Physician profile
Deborah A Glidden
NPI 1659367589
$69,176.46
in general payments reported to CMS, 2019-2025
10 companies · $461 in 2025
The $461 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $28K · 2022: $27K · 2023: $9,022 · 2024: $3,851 · 2025: $461.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,300 · Travel and Lodging: $5,373 · Food and Beverage: $1,606 · Education: $54.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,300.00 |
| Travel and Lodging | $5,373.16 |
| Food and Beverage | $1,605.52 |
| Education | $54.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $60,688.98 | 2021-2024 | Parsabiv |
| Bayer Healthcare Pharmaceuticals INC. | $6,598.09 | 2021-2022 | |
| Vifor Pharma, INC. | $571.74 | 2021-2024 | Veltassa, Korsuva |
| Fresenius USA Marketing, INC. | $493.40 | 2021-2025 | Velphoro, Velphoro |
| Astrazeneca Pharmaceuticals LP | $226.20 | 2021-2022 | |
| Ardelyx, INC. | $222.75 | 2024-2025 | Xphozah 30 Mg |
| Akebia Therapeutics INC | $154.98 | 2021-2025 | Vafseo |
| Baxter Healthcare | $145.67 | 2023 | |
| Opko Pharmaceuticals, LLC | $54.35 | 2025 | Rayaldee |
| Novartis Pharmaceuticals Corporation | $20.30 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deborah Glidden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.